Last-Resort drug opens for brain cancer patients
NCT ID NCT06404034
First seen Mar 09, 2026 · Last updated May 09, 2026 · Updated 7 times
Summary
This program provides gallium maltolate, an experimental oral drug, to adults with glioblastoma that has come back or not responded to standard treatments. It is for patients who have run out of other options and may still benefit. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Partners of Nebraska
Lincoln, Nebraska, 68516, United States
-
Northwell Health
New York, New York, 10075, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.